| Potentiating the antitumour response of CD8+ T cells by modulating cholesterol metabolism W Yang, Y Bai, Y Xiong, J Zhang, S Chen, X Zheng, X Meng, L Li, J Wang, ... Nature 531 (7596), 651-655, 2016 | 753 | 2016 |
| COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas X Ren, W Wen, X Fan, W Hou, B Su, P Cai, J Li, Y Liu, F Tang, F Zhang, ... Cell 184 (7), 1895-1913. e19, 2021 | 609 | 2021 |
| Dendritic cells in the thymus contribute to T-regulatory cell induction AI Proietto, S van Dommelen, P Zhou, A Rizzitelli, A D'Amico, RJ Steptoe, ... Proceedings of the National Academy of Sciences 105 (50), 19869-19874, 2008 | 389 | 2008 |
| Somatic single hits inactivate the X-linked tumor suppressor FOXP3 in the prostate L Wang, R Liu, W Li, C Chen, H Katoh, GY Chen, B McNally, L Lin, P Zhou, ... Cancer cell 16 (4), 336-346, 2009 | 258 | 2009 |
| In vivo discovery of immunotherapy targets in the tumour microenvironment P Zhou, DR Shaffer, DA Alvarez Arias, Y Nakazaki, W Pos, AJ Torres, ... Nature 506 (7486), 52-57, 2014 | 253 | 2014 |
| Simultaneous improvement for four quality traits of Zhenshan 97, an elite parent of hybrid rice, by molecular marker-assisted selection P Zhou, Y Tan, Y He, C Xu, Q Zhang TAG Theoretical and Applied Genetics 106 (2), 326-331, 2003 | 250 | 2003 |
| Stress–glucocorticoid–TSC22D3 axis compromises therapy-induced antitumor immunity H Yang, L Xia, J Chen, S Zhang, V Martin, Q Li, S Lin, J Chen, J Calmette, ... Nature medicine 25 (9), 1428-1441, 2019 | 220 | 2019 |
| FBXO38 mediates PD-1 ubiquitination and regulates anti-tumour immunity of T cells X Meng, X Liu, X Guo, S Jiang, T Chen, Z Hu, H Liu, Y Bai, M Xue, R Hu, ... Nature 564 (7734), 130-135, 2018 | 200 | 2018 |
| Increased vessel perfusion predicts the efficacy of immune checkpoint blockade X Zheng, Z Fang, X Liu, S Deng, P Zhou, X Wang, C Zhang, R Yin, H Hu, ... The Journal of clinical investigation 128 (5), 2104-2115, 2018 | 179 | 2018 |
| cGAS/STING axis mediates a topoisomerase II inhibitor–induced tumor immunogenicity Z Wang, J Chen, J Hu, H Zhang, F Xu, W He, X Wang, M Li, W Lu, G Zeng, ... The Journal of clinical investigation 129 (11), 4850-4862, 2019 | 158 | 2019 |
| CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia J Wang, S Chen, W Xiao, W Li, L Wang, S Yang, W Wang, L Xu, S Liao, ... Journal of hematology & oncology 11, 1-13, 2018 | 157 | 2018 |
| High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39+ CD8+ T cells T Liu, J Tan, M Wu, W Fan, J Wei, B Zhu, J Guo, S Wang, P Zhou, H Zhang, ... Gut 70 (10), 1965-1977, 2021 | 88 | 2021 |
| Dysregulated adaptive immune response contributes to severe COVID-19 K Yu, J He, Y Wu, B Xie, X Liu, B Wei, H Zhou, B Lin, Z Zuo, W Wen, W Xu, ... Cell research 30 (9), 814-816, 2020 | 72 | 2020 |
| Defined tumor antigen-specific T cells potentiate personalized TCR-T cell therapy and prediction of immunotherapy response J He, X Xiong, H Yang, D Li, X Liu, S Li, S Liao, S Chen, X Wen, K Yu, ... Cell research 32 (6), 530-542, 2022 | 68 | 2022 |
| The combination of immune checkpoint blockade and angiogenesis inhibitors in the treatment of advanced non-small cell lung cancer S Ren, X Xiong, H You, J Shen, P Zhou Frontiers in Immunology 12, 689132, 2021 | 63 | 2021 |
| Intracellular CD24 disrupts the ARF–NPM interaction and enables mutational and viral oncogene-mediated p53 inactivation L Wang, R Liu, P Ye, C Wong, GY Chen, P Zhou, K Sakabe, X Zheng, ... Nature communications 6 (1), 5909, 2015 | 58 | 2015 |
| Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma Y Que, XL Zhang, ZX Liu, JJ Zhao, QZ Pan, XZ Wen, W Xiao, BS Xu, ... Journal for ImmunoTherapy of Cancer 9 (2), 2021 | 51 | 2021 |
| Disruption of CD8+ Treg Activity Results in Expansion of T Follicular Helper Cells and Enhanced Antitumor Immunity DA Alvarez Arias, HJ Kim, P Zhou, TAW Holderried, X Wang, G Dranoff, ... Cancer immunology research 2 (3), 207-216, 2014 | 48 | 2014 |
| Blocking interaction between SHP2 and PD‐1 denotes a novel opportunity for developing PD‐1 inhibitors Z Fan, Y Tian, Z Chen, L Liu, Q Zhou, J He, J Coleman, C Dong, N Li, ... EMBO molecular medicine 12 (6), e11571, 2020 | 46 | 2020 |
| Melatonin synergizes BRAF-targeting agent vemurafenib in melanoma treatment by inhibiting iNOS/hTERT signaling and cancer-stem cell traits J Hao, W Fan, Y Li, R Tang, C Tian, Q Yang, T Zhu, C Diao, S Hu, M Chen, ... Journal of Experimental & Clinical Cancer Research 38, 1-15, 2019 | 45 | 2019 |
